News
Lush Prize Conference 2014
Sunday, 12 October 2014 17:47On November 14th the LUSH Company is hosting a conference in London. It will be discussed whether the 3R concept (reduce, refine, replace of animal experiments) developed by Russel & Burch in the 1950s “has had its day” or whether the new tox21 concept that entails a total replacement of animals, for instance using pathway-based approaches, is still so far off that 3R will stay relevant for many years to come.
Blind study on in vitro cardiotoxicity
Thursday, 09 October 2014 20:23Researchers from the German Centre for Cardiovascular Research (DZHK) led by Prof. Thomas Eschenhagen and colleagues from the UK and the Netherlands are going to use artificial heart cells to study whether it is possible to predict side effects of pharmaceuticals on the heart. That way animal experiments could be reduced or fully eliminated.
Academic Enterprise Award for non-animal test methods
Thursday, 09 October 2014 20:14Jan Lichtenberg and Melanie Aregger from the Swiss company InSphero AG have received the Life Sciences Award from Science|Business, a Belgian-British media association and innovation network. The jury is drawn from academia, industry and venture capital.
Switzerland: Info-Day on Green Toxicology
Monday, 06 October 2014 20:12On 23 October, Empa Swiss Federal Laboratories for Materials Science and Technology will host an information day on green toxicology in Dübendorf, Switzerland. The registration deadline is the 15th of October.
Berlin: 3rd Symposium on Alternatives to Animal Testing
Wednesday, 01 October 2014 20:06On 30 September 2014, the Symposium on Alternatives to Animal Testing took place at the Federal Institute for Risk Assessment (BfR) in Berlin, hosted by the State Office of Health and Social Affairs Berlin. What could be heard there was encouraging.
In vitro research: Cytomegalovirus may cause vascular diseases
Monday, 22 September 2014 20:05With the help of human cell cultures, a research team from the University of Münster and colleagues from Ulm and Maastricht have gained important insights into the molecular mechanism of the human cytomegalovirus that may lead to the development of arteriosclerosis.
Preclinicals and bioavailability: would some drugs get developed today?
Thursday, 18 September 2014 20:02The pharmaceutical computer scientist Dr. Wolfgang Boomgaarden has analysed a wide range of data available on the bioavailability of substances in humans and animals. He found that many drugs that have become commercial success stories, such as Omeprazole, should not normally have been developed at all, because bioavailability in animals, which is required for in the pre-clinical studies, is in fact far too low.
Regenerative medicine as a scientific way of conducting research without animal experiments
Friday, 12 September 2014 19:59Regenerative medicine (cell and tissue replacement therapy) is based on stem cell research, which is a cell biology research method that per se does not depend on animal testing.
Database for Systemic Toxicity Launched
Friday, 05 September 2014 19:55The European Joint Research Centre (JRC) has launched a centralised compilation of data for systemic toxicity - the ToxBank Data Warehouse - for which public access is now available upon request.
News from the 9th World Congress on Alternatives and Animal Use in the Life Sciences
Sunday, 31 August 2014 19:28This year’s World Congress on Alternatives and Animal Use in the Life Sciences took place 24–28 August 2014 in Prague. More than 1,000 participants from 49 countries presented their research results on replacing, reducing and refining animal tests.
Unlike the annual European Congress on Alternatives to Animal Testing in Linz, Austria, which concentrates on replacement methods for animal experiments, the World Congress is thematically broader, also addressing new insights into reducing the numbers of animals used and refining animal test methods.
Dr. rer. nat.
Menschen für Tierrechte - Tierversuchsgegner Rheinland-Pfalz e.V.